PINNED
PINNED
Pharma Horizons: leading-edge formulation
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
List view / Grid view
Articles
The next generation handheld Raman spectrometer: the Thermo Scientific TruScan RM
Erica Hirsch, Product Manager at Thermo Fisher Scientific looks at the next generation handheld Raman spectrometer the Thermo Scientific TruScan RM...
The role of proteomics in the development of personalised cancer medicine
18 April 2013 | By Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London
Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the…
The central role of excipients in drug formulation
18 April 2013 | By Pascal Furrer, Pharmacist
Active substances are rarely administered alone. For example, levothyroxine, a synthetic form of the thyroid hormone, indicated in the treatment of hypothyroidism, is administered at a very low dosage, ranging from 15 μg to 200 μg. These very small amounts of powder mean that it is not possible to manufacture…
Under the MICROSCOPE with Volker J. Frost, Chief Profit Center Spectroscopy, Metrohm AG
Metrohm, a leading manufacturer of instruments for chemical analysis and FOSS, a leading supplier of dedicated analytical solutions to optimise quality and control, have entered into a strategic alliance strengthening the two companies’ leading positions in their respective key markets. In this strategic alliance, Metrohm will become the sole global…
Mass Spectrometry In-Depth Focus 2013
In this Mass Spectrometry In-Depth Focus: Corticosteroids and mass spectrometry; latest applications using LC/MS; Multi-analyte LC-MS/MS assays for the quantification of endogenous compounds during the development of drugs and companion diagnostics...
Stem Cells In-Depth Focus 2013
In this Stem Cells In-Depth Focus: The promise held by induced pluripotent stem cells for research and regenerative medicine; Workshop preview – Cell based assays for screening; Cardiac stem cells; Stem Cells Roundtable...
Gene to drugs: can expression be the key to new discoveries?
25 February 2013 | By Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky
Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new…
Industry Expert Panel
Welcome to European Pharmaceutical Review’s Industry Expert Panel. We have assembled a panel of authoritative voices from the pharmaceutical industry to speak on a wide range of issues that affect this industry, sharing their expertise and insight with our readers.
Applications of solid-state NMR spectroscopy to pharmaceuticals
21 February 2013 | By Eric Munson, Patrick DeLuca Endowed Professor in Pharmaceutical Technology, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky
Solid-state NMR spectroscopy (SSNMR) has emerged as an extremely powerful analytical technique for the characterisation of pharmaceuticals[1-5]. Despite its capability, SSNMR is still not used ubiquitously in the pharmaceutical industry. Several factors contribute to this, including cost and analysis time, but two of the major reasons are understanding the full…
Jack Zhou, Chief Operating Officer at B&W Tek discusses their handheld Raman spectrometer, the NanoRam®
21 February 2013 | By Jack Zhou, Chief Operating Officer at B&W Tek
Established in 1997, B&W Tek first developed a comprehensive OEM laser product line based on diode lasers in its first four years before adding an array-based spectrometer product line for OEM customers in 2001...
Extracellular microRNA: the promises for the diagnostics of multiple diseases
21 February 2013 | By Andrey Turchinovich and Barbara Burwinkel, German Cancer Research Center
This mini-review aims to summarise recent advances in the field of molecular diagnostic of diseases using extracellular circulating miRNA in biological fluids. We will also discuss obstacles in developing miRNAs as circulating biomarkers as well as the potential future of the field.
Getting to grips with drug resistance in the human protein kinase superfamily
21 February 2013 | By Patrick A Eyers, Department of Oncology, Sheffield Cancer Research Centre, University of Sheffield
Protein kinases represent a vast, partially untapped resource of drug targets for therapeutic intervention in human disease. The remarkable success of the tyrosine kinase inhibitor Imatinib, which is now the first-line therapy in Philadelphia-positive tyrosine kinase inhibitor Imatinibhas galvanised biomedical researchers in an attempt to repeat the landmark success of…
Improving the quantitation of live antigens used to produce rabbit generated serotype specific antiserum
21 February 2013 | By Michael J. Miller, President, Microbiology Consultants, LLC, Silvia Fragoeiro, Ananthi Ramachandran and Paul van Empel MSD Animal Health
This is the first paper in our continuing series on Rapid Microbiological Methods (RMM) that will appear in European Pharmaceutical Review during 2013. Flow cytometry represents one of a variety of viability-based RMM technologies that are currently available to the pharmaceutical industry. In flow cytometry, individual particles are counted as…
Practical Workshop – Biochemical Assays for Screening
21 February 2013 | By Sheraz Gul, Head of Biology at European ScreeningPort, Hamburg, Germany
Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of universities worldwide that now host infrastructure such as compound libraries and automated screening centres[1-3]. An archetypal small molecule drug discovery project will aim to identify…
The evolution of the Contract Research Organisation and the future of the pharmaceutical industry
This article discusses how the pharmaceutical industry can leverage its competencies in outsourcing to accelerate time to market, improve quality and increase innovation at all stages of the drug discovery and development process. The pharmaceutical industry is being battered by a perfect storm of not just one but three major…
